Glucagon-like Peptide-1 Receptor Agonists: Additional Improvement of Erectile Dysfunction in Type 2 Diabetes

References

1. SaloniaA. BettocchiC. BoeriL. European association of urology guidelines on sexual and reproductive health-2021 update: Male sexual dysfunction.Eur. Urol.202180333335710.1016/j.eururo.2021.06.007 34183196
   [Google Scholar]
2. AndersonD. LaforgeJ. RossM.M. Male sexual dysfunction.Health Psychol. Res.20221033753310.52965/001c.37533 35999971
   [Google Scholar]
3. KouidratY. PizzolD. CoscoT. High prevalence of erectile dysfunction in diabetes: A systematic review and meta‐analysis of 145 studies.Diabet. Med.20173491185119210.1111/dme.13403 28722225
   [Google Scholar]
4. KamenovZ.A. A comprehensive review of erectile dysfunction in men with diabetes.Exp. Clin. Endocrinol. Diabetes20151233141158 25502583
   [Google Scholar]
5. WangC.M. WuB.R. XiangP. XiaoJ. HuX.C. Management of male erectile dysfunction: From the past to the future.Front. Endocrinol.202314114883410.3389/fendo.2023.1148834 36923224
   [Google Scholar]
6. PatouliasD. PopovicD.S. StoianA.P. JanezA. SahebkarA. RizzoM. Effect of semaglutide versus other glucagon-like peptide-1 receptor agonists on cardio-metabolic risk factors in patients with type 2 diabetes: A systematic review and meta-analysis of head-to-head, phase 3, randomized controlled trials.J. Diabetes Complications202337810852910.1016/j.jdiacomp.2023.108529 37301063
   [Google Scholar]
7. YuanP. MaD. GaoX. Liraglutide ameliorates erectile dysfunction via regulating oxidative stress, the RhoA/ROCK pathway and autophagy in diabetes mellitus.Front. Pharmacol.202011125710.3389/fphar.2020.01257 32903510
   [Google Scholar]
8. DalakliogluS. TasatargilA. KuscuN. Protective effect of exendin-4 treatment on erectile dysfunction induced by chronic methylglyoxal administration in rats.Peptides20181061810.1016/j.peptides.2018.05.005 29792899
   [Google Scholar]
9. LiscoG. BartolomeoN. De TullioA. Long‐acting glucagon‐like peptide 1 receptor agonists boost erectile function in men with type 2 diabetes mellitus complaining of erectile dysfunction: A retrospective cohort study.Andrology202412363364210.1111/andr.13519 37615353
   [Google Scholar]
10. DefeudisG. Di TommasoA.M. Di RosaC. The role of antihyperglycemic drugs and diet on erectile function: Results from a perspective study on a population with prediabetes and diabetes.J. Clin. Med.20221112338210.3390/jcm11123382 35743453
    [Google Scholar]
11. GiagulliV.A. CarboneM.D. RamunniM.I. Adding liraglutide to lifestyle changes, metformin and testosterone therapy boosts erectile function in diabetic obese men with overt hypogonadism.Andrology2015361094110310.1111/andr.12099 26447645
    [Google Scholar]
12. BajajH.S. GersteinH.C. Rao-MelaciniP. Erectile function in men with type 2 diabetes treated with dulaglutide: An exploratory analysis of the REWIND placebo-controlled randomised trial.Lancet Diabetes Endocrinol.20219848449010.1016/S2213‑8587(21)00115‑7 34153269
    [Google Scholar]
13. YangB. ChengH. HuY. Effects of anti-diabetic drugs on erectile dysfunction: A systematic review and meta-analysis.Diabetes Metab. Syndr. Obes.20251846747810.2147/DMSO.S503216 39990178
    [Google Scholar]
14. SalvioG CiarloniA AmboN Effects of glucagon‐like peptide 1 receptor agonists on testicular dysfunction: A systematic review and meta‐analysis. Andrology 2025; andr.70022.10.1111/andr.7002240105090
    [Google Scholar]
15. AnH. XieK. GanH. Glucagon-like peptide-1 receptor agonists and the risk of erectile dysfunction: A drug target Mendelian randomization study.Front. Endocrinol.202415144839410.3389/fendo.2024.1448394 39605940
    [Google Scholar]
16. Pourabhari LangroudiA. ChenA.L. BasranS. Male sexual dysfunction associated with GLP-1 receptor agonists: A cross-sectional analysis of FAERS data.Int. J. Impot. Res.2025Epub ahead of print10.1038/s41443‑025‑01061‑2 40240532
    [Google Scholar]
17. AbleC. LiaoB. SaffatiG. Prescribing semaglutide for weight loss in non-diabetic, obese patients is associated with an increased risk of erectile dysfunction: A TriNetX database study.Int. J. Impot. Res.202537431531910.1038/s41443‑024‑00895‑6 38778151
    [Google Scholar]